Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Chi Leung Chiang"'
Autor:
Shing Fung Lee, Horace C. W. Choi, Sik Kwan Chan, Ka On Lam, Victor H. F. Lee, Irene O. L. Wong, Chi Leung Chiang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesWe aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-lin
Publikováno v:
Cancers
Volume 13
Issue 5
Cancers, Vol 13, Iss 931, p 931 (2021)
Volume 13
Issue 5
Cancers, Vol 13, Iss 931, p 931 (2021)
Simple Summary There is a growing body of literature demonstrating high cancer drug costs relative to the benefits provided to patients treated on a large scale. We examined the cost-effectiveness of atezolizumab–bevacizumab for the first-line trea
Autor:
Chi Leung Chiang, Andrea K. Ng, Miguel Angel Luque-Fernandez, Paul J. Catalano, Shing Fung Lee, Yu-Hui Chen, Eric Yuk Fai Wan, Ming-Hui Chen, Ian C. K. Wong
Publikováno v:
Blood Adv
Digibug. Repositorio Institucional de la Universidad de Granada
instname
Digibug: Repositorio Institucional de la Universidad de Granada
Universidad de Granada (UGR)
Digibug. Repositorio Institucional de la Universidad de Granada
instname
Digibug: Repositorio Institucional de la Universidad de Granada
Universidad de Granada (UGR)
Evidence regarding the dose-related impact of doxorubicin on subsequent cardiovascular diseases (CVDs) in Asian patients with diffuse large B-cell lymphoma (DLBCL) without preexisting CVDs is lacking. From a territory-wide electronic database in Hong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aa3187a31d50f73f5398ab38343ab1c
http://hdl.handle.net/10481/64301
http://hdl.handle.net/10481/64301
Publikováno v:
Annals of Oncology. 32:S97
Autor:
Conrad Lee, Kwong Chuen Leung, Marc K. C. Chong, Steward Tung, Jacques Jolivet, Francis A. S. Lee, Maria Lai, Chi-Leung Chiang, Chloe Kwok, Philip W.K. Kwong, Steven Kin-Lok Siu, FY Cheung, Benny Zee
Publikováno v:
American Journal of Clinical Oncology. 39:609-613
Objectives This multicenter, randomized, open-label, phase II trial evaluated the efficacy and safety of AEG35156 in addition to sorafenib in patients with advanced hepatocellular carcinoma (HCC), as compared with sorafenib alone. Methods Eligible pa
Publikováno v:
Prostate cancer and prostatic diseases. 23(1)
Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the co
Publikováno v:
JAMA Network Open
Key Points Question Is pembrolizumab a cost-effective second-line therapy for advanced hepatocellular carcinoma from the US perspective? Findings In this economic evaluation of data from the KEYNOTE-240 randomized trial, the incremental number of qua
Autor:
Chi-Leung Chiang, Yundai Chen, F.M. Kong, Pan-Chyr Yang, Y. Hu, Albert C. Y. Chan, Zhao-Chong Zeng, S. Du, Wei Zhang, G. Shi
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:S85
Autor:
Stewart Y. Tung, Venus Lee, G Law, Mark K. H. Chan, Hollis Luk, Oliver Blanck, Kwong Lok Siu, Francis A. S. Lee, Frank C.S. Wong, Chi-Leung Chiang, N. Y. Sin
Publikováno v:
Strahlentherapie und Onkologie. 192:92-101
The purpose of this work was to investigate the potential of lipiodol as a direct tumor surrogate alternative to the diaphragm surrogate on four-dimensional cone-beam computed tomography (4D-CBCT) image guidance for stereotactic radiotherapy of hepat
Publikováno v:
Annals of Oncology. 30:ix69
Background The treatment landscape of metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly over past few years. Following publications of several large-scale randomised controlled trials (RCTs) Abiraterone (AA) and Docetaxel (D